Collaborations

Anaveon is open for collaborations with biotechnology, pharmaceutical,  and other therapeutics partners to discover, develop and commercialize innovative treatments in the fields of oncology (including immuno-oncology) and immune-related disorders.  We welcome opportunities to partner through in- and out-licensure, co-development, region-specific agreements, joint ventures, and other collaborations.

Our company’s strengths include:

 

Innovation

  • cutting-edge science with a tailored approach and a focus on biologic therapeutics and immunology

Speed

  • rapid execution from drug design and discovery through preclinical and clinical development

Experience

  • cross-functional team with decades of experience with multiple indications in large pharma, specialty therapeutics and entrepreneurial biotechs

Operations

  • in-house laboratories, CMC development expertise, and broad clinical strategy and operations capabilities

Excellence

  • world-renowned scientific advisors, top-tier investors, quality heritage, honest and collaborative values

 

If you wish to learn more about collaborating with Anaveon, please contact us:

Anaveon has entered into a clinical trial collaboration and supply agreement with MSD, to evaluate Anaveon’s wholly-owned drug candidate ANV600 in combination with KEYTRUDA in clinical trials. Under the terms of the agreement, MSD will supply KEYTRUDA. Anaveon retains all worldwide rights to ANV600.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept